Federal Circuit Court of Appeals Newswire

Federal Circuit Court of Appeals Newswire

Comprehensive Real-Time News Feed for Federal Circuit Court of Appeals.

Results 1 - 20 of 673 in Federal Circuit Court of Appeals

  1. StrikeForce Technologies Immediately Appeals Court's RulingRead the original story

    Friday Dec 8 | Customer Interaction Solutions

    StrikeForce Technologies, Inc. . On December 1, 2017, The United States District Court for the Central District of California issued an opinion in the StrikeForce Technologies, Inc. v.

    Comment?

  2. Contingent Patent Ownership Is Not Sufficient For Federal Court JurisdictionRead the original story w/Photo

    Friday Dec 8 | JD Supra

    ... event occurs, is not enough. This seems like an obvious rule, but it ended up before the Federal Circuit Court of Appeals. The case is First Data Corp. v. Inselberg (Fed. Cir. 9/15/17). The defendants were Eric Inselberg, an inventor, and his ...

    Comment?

  3. PTAB Issues Guidelines For Motions To AmendRead the original story w/Photo

    Thursday Dec 7 | JD Supra

    An en banc panel of the Court of Appeals for the Federal Circuit in the case of Aqua Products, Inc. v. Matal recently held that in an inter-partes proceeding, the burden of persuasion rests with the challenger to persuade the PATB that substitute claims proposed by a patent owner in a motion to amend are unpatentable.

    Comment?

  4. Supreme Court Hears Argument in SAS Institute, Inc. v. Complementsoft, LLCRead the original story w/Photo

    Wednesday Dec 6 | jdsupra.com

    Perhaps overlooked in the widespread assessments of the Supreme Court's questioning of the parties in Oil States Energy Services, LLC. v. Greene's Energy Group, LLC is the argument before the Court in SAS Institute, Inc. v.

    Comment?

  5. Why Oracle's Chances Look Slim in Latest Federal Circuit Appeal Against GoogleRead the original story

    Wednesday Dec 6 | Law.com

    The following article is an excerpt from Skilled in the Art , Law.com's new email briefing on Everything IP. Scott Graham focuses on intellectual property and the U.S. Court of Appeals for the Federal Circuit.

    Comment?

  6. Skilled in the Art: Why Oracle's Chances Look Slim in Second Java AppealRead the original story w/Photo

    Tuesday Dec 5 | Law.com

    Welcome to Skilled in the Art . I'm Scott Graham , Law.com's lead reporter on intellectual property.

    Comment?

  7. Federal Circuit Slams PTAB Amendment PolicyRead the original story w/Photo

    Tuesday Dec 5 | JD Supra

    On October 4, 2017, the Court of Appeals for the Federal Circuit, sitting en banc , overruled an earlier panel decision and found that the Patent Trial and Appeal Board had been impermissibly placing the burden of proving the patentability of amended claims on the Patent Owner, rather than the Petitioner. See, Aqua Products v.

    Comment?

  8. 'Troll King' Intellectual Ventures Wins Antitrust War With Capital OneRead the original story w/Photo

    Monday Dec 4 | Law.com

    Scott Graham writes about intellectual property and the U.S. Court of Appeals for the Federal Circuit. Contact him at [email protected]

    Comment?

  9. Federal Circuit Clarifies Waiver Of Venue Issue In Light Of TC...Read the original story w/Photo

    Friday Dec 1 | JD Supra

    The U.S. Supreme Court's May 22, 2017 ruling in TC Heartland v. Kraft Foods held that personal jurisdiction alone does not convey venue for patent cases under the patent venue statute.

    Comment?

  10. Nike and adidas Go Head-To-Head in Legal Fight Over Flyknit PatentRead the original story w/Photo

    Thursday Nov 30 | Hypebeast.com

    It's not often that you see adidas and Nike in the same header without there being a point of contention - and this time is no different. The Three Stripes and the Swoosh are reigniting a legal feud over Nike's Flyknit patent.

    Comment?

  11. When a Park in the Sky Leads to a Lawsuit - Three Strategies for Success in High-Stakes LitigationRead the original story w/Photo

    Thursday Nov 30 | JD Supra

    In 2002, New York City announced its support for preserving the High Line - turning an unused elevated railroad into a thriving park in the heart of Manhattan's West Side. Fifteen years later, it is one of the City's top tourist attractions and is visited by millions of people.

    Comment?

  12. 'CRISPR' and the Future of HumanityRead the original story w/Photo

    Thursday Nov 30 | Law.com

    Berkeley researchers lost big in a Patent Trial and Appeal Board fight over a gene-splicing patent worth billions of dollars. PTAB found a Broad Institute at the Massachusetts Institute of Technology patent for a technique called CRISPR-Cas9 in multicellular organisms didn't violate Berkeley's patent for single-celled organisms.

    Comment?

  13. New PTO Rule on Attorney-Client Privilege Before the PTABRead the original story w/Photo

    Thursday Nov 30 | JD Supra

    The US Patent and Trademark Office issued a new rule on attorney-client privilege for trials before the Patent Trial and Appeal Board on November 7, 2017. The new rule takes effect December 7, 2017.

    Comment?

  14. Supreme Court Removes Patent Litigation from the Heartland of TexasRead the original story w/Photo

    Thursday Nov 30 | JD Supra

    For years, patent assertion entities have filed patent lawsuits against retailers in federal court in Texas. The Supreme Court's recent decision in TC Heartland LLC v.

    Comment?

  15. Functional Claim Language Describing System Capabilities May Undermine IndefinitenessRead the original story w/Photo

    Wednesday Nov 29 | JD Supra

    Addressing issues of indefiniteness and claim construction, the US Court of Appeals for the Federal Circuit affirmed the district court's claim construction but reversed its indefiniteness decision, concluding that the system claims at issue did not impermissibly claim two different subject matter classes. MasterMine Software, Inc. v.

    Comment?

  16. Extrinsic Evidence Makes a "Swell" Difference in Claim ConstructionRead the original story w/Photo

    Wednesday Nov 29 | JD Supra

    Upholding a Patent Trial and Appeal Board patentability finding, the US Court of Appeals for the Federal Circuit found that the PTAB did not err in determining the broadest reasonable construction of a claim term and finding that the record did not establish anticipation or obviousness. Organik Kimya AS v.

    Comment?

  17. Federal Circuit Clarifies Probative Value of Patent Dance StatementsRead the original story w/Photo

    Wednesday Nov 29 | jdsupra.com

    The Situation: The Biologics Price Competition and Innovation Act was considered in a November 2017 decision by the United States Court of Appeals for the Federal Circuit. The Result: The court found that the commercial marketing of Apotex's proposed biosimilar versions of Amgen's Neulasta and Neupogen would not infringe on a patent held by Amgen.

    Comment?

  18. Cat on a Hot Asphalt Roof? PTAB's BRI Is Too NarrowRead the original story w/Photo

    Wednesday Nov 29 | jdsupra.com

    Addressing a Patent Trial and Appeal Board decision upholding patentability of the challenged claims in an inter partes review, the US Court of Appeals for the Federal Circuit rejected the PTAB's broadest reasonable claim construction as unduly narrow. Owens Corning v.

    Comment?

  19. Government Contractor Awarded Equitable Adjustment for Negligent...Read the original story w/Photo

    Tuesday Nov 28 | jdsupra.com

    A recent decision by the United States Court of Federal Claims reminds us how important the Government's estimated quantities are, even in a fixed price contract. In Agility Defense & Government Services, Inc. v United States , the Court of Federal Claims awarded Agility $6,906,339.20, plus interest, representing the cost of additional, unanticipated work Agility had to perform on the contract as a result of the Government's negligent quantities estimates.

    Comment?

  20. BPCIA Litigation RoundupRead the original story w/Photo

    Tuesday Nov 28 | JD Supra

    Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates .

    Comment?